Sumitomo Pharma Co

Sumitomo Pharma Co ROCE

The Return on Capital Employed (ROCE) of Sumitomo Pharma Co (4506.T) as of Nov 20, 2026 is 17.21 %. In the previous year, Return on Capital Employed (ROCE) was 13.23 % — a change of 30.10% (higher).

ROCE

17.21 %

YoY

30.10%

Last updated:

In 2026, Sumitomo Pharma Co's return on capital employed (ROCE) was 17.21 %, a 30.10% increase from the 13.23 % ROCE in the previous year.

The Sumitomo Pharma Co ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2019
11.48 JPY
Jan 1, 2020
8.08 JPY
Jan 1, 2021
10.55 JPY
Jan 1, 2022
8.40 JPY
Jan 1, 2023
2.75 JPY
Jan 1, 2024
-0.94 JPY
Jan 1, 2025
13.23 JPY
Jan 1, 2026
17.21 JPY
The Sumitomo Pharma Co ROCE history
YEARROCEYoY
17.21 %+30.10%
13.23 %-1,500.46%
-0.94 %-134.30%
2.75 %-67.20%
8.40 %-20.41%
10.55 %+30.54%
8.08 %-29.63%
11.48 %-34.72%
17.59 %+18.95%
14.79 %+78.81%
8.27 %+60.28%
5.16 %-51.20%
10.57 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sumitomo Pharma Co Stock analysis

What does Sumitomo Pharma Co do? Sumitomo Dainippon Pharma Co Ltd is a biopharmaceutical company headquartered in Osaka, Japan. It was originally founded as Dainippon Pharmaceutical Co. Ltd in 1885 and later merged with Sumitomo Pharmaceuticals in 2005 to form the new Sumitomo Dainippon Pharma. The company operates in various areas, such as psychiatric and neurological medicine, oncology, dermatology, and infectious diseases. The products include both prescription and over-the-counter medications. In psychiatric and neurological medicine, Sumitomo Dainippon Pharma offers drugs that can be used to treat depression, anxiety disorders, schizophrenia, and bipolar disorders. One of the most well-known medications in this category is the antipsychotic Latuda, which is used for schizophrenia and bipolar disorder. In oncology, Sumitomo Dainippon Pharma has developed medications that can be used in the treatment of cancers such as lung, liver, pancreatic, colorectal, and blood cancer. The company is also involved in developing treatments for rare forms of cancer and immune-mediated diseases. In dermatology, Sumitomo Dainippon Pharma has developed medications for the treatment of skin and nail infections, psoriasis, and atopic dermatitis. The company is also working on innovative treatment approaches for skin cancer and other types of skin diseases. Sumitomo Dainippon Pharma is also involved in the development of treatments for infectious diseases, including medications for HIV and hepatitis C. The business model of Sumitomo Dainippon Pharma is based on the development of new drugs and the marketing of prescription and over-the-counter medications on a global level. The company focuses on researching and developing drugs that can address significant medical needs and that differentiate themselves from other medications on the market. The products are registered and marketed in various countries, especially in the US and Japan. Sumitomo Dainippon Pharma invests significantly in research and development. The company has R&D sites in Japan, the US, UK, and Ireland. It also collaborates with other companies to leverage innovative technologies and accelerate the development of new medications. Overall, Sumitomo Dainippon Pharma has a long history in the pharmaceutical industry and is committed to creating a wide range of medications and therapies for various diseases and conditions. The company is dedicated to improving the lives of patients and contributing to the well-being of society as a whole. Sumitomo Pharma Co is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Sumitomo Pharma Co's Return on Capital Employed (ROCE)

Sumitomo Pharma Co's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Sumitomo Pharma Co's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Sumitomo Pharma Co's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Sumitomo Pharma Co’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Sumitomo Pharma Co stock

Return on Capital Employed (ROCE) of Sumitomo Pharma Co is 17.21 % in 2026.

Return on Capital Employed (ROCE) of Sumitomo Pharma Co changed from 13.23 % to 17.21 %, representing a 30.10% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Sumitomo Pharma Co since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Sumitomo Pharma Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Sumitomo Pharma Co

All Key Metrics — Sumitomo Pharma Co